
If you were wondering why the White House suddenly took an interest in the consequences of tax inversion deals last spring, here is the reason – a pair of Wall Streeters with ties to the Obama administration made some calls on behalf of
AstraZeneca which, you may recall, was trying to fend off an unwanted bid from
Pfizer. Pfizer cited a tax inversion as one reason for its offer.
No comments:
Post a Comment